It has been reported that nearly 40–50% of breast tumors harbor heterozygous PTEN loss, whereas functional PTEN loss because of mutations has been detected in 5–10% of breast tumors, and the frameshift is the most common mechanism (Coughlin et al., 2010; Bazzichetto et al., 2019). Here, PTEN is linked to breast neoplasm.